H.C. Wainwright analyst Raghuram Selvaraju started Provention Bio with a Buy rating and $7.50 price target. Provention is a “virtual, rapidly emerging biotechnology company focused on treatment of inflammatory and autoimmune diseases,” Selvaraju tells investors in a research note. He sees “substantial” market opportunities for the company that underserved by existing drugs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.